You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDomperidone
Accession NumberDB01184  (APRD00418)
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
DescriptionA specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms. [PubChem]
Structure
Thumb
Synonyms
1-(3-(4-(5-chloro-2-oxo-2,3-Dihydrobenzo[D]imidazol-1-yl)piperidin-1-yl)propyl)-1H-benzo[D]imidazol-2(3H)-one
5-chloro-1-(1-(3-(2-oxo-1-Benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone
5-chloro-1-(1-(3-(2-oxo-2,3-Dihydrobenzo[D]imidazol-1-yl)propyl)piperidin-4-yl)-1H-benzo[D]imidazol-2(3H)-one
5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one
Domperidona
Domperidonum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-domperidonetablet10 mgoralAvanstra Inc2011-09-152014-08-21Canada
Bio-domperidonetablet10 mgoralBiomed Pharma2016-04-26Not applicableCanada
Dom-domperidonetablet10 mgoralDominion Pharmacal1998-09-17Not applicableCanada
Domperidonetablet10 mgoralSanis Health Inc2010-05-12Not applicableCanada
Domperidonetablet10 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Domperidonetablet10 mgoralSivem Pharmaceuticals Ulc1998-09-03Not applicableCanada
Domperidone-10tablet10 mgoralPro Doc Limitee1998-07-13Not applicableCanada
Ftp-domperidone Maleatetablet10 mgoralGmd Distribution Inc.1998-10-092005-08-05Canada
Ipg-domperidonetablet10 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-domperidonetablet10 mgoralJamp Pharma Corporation2011-10-07Not applicableCanada
Mar-domperidonetablet10 mgoralMarcan Pharmaceuticals Inc2014-01-02Not applicableCanada
Motilidonetablet10 mgoralTechnilab Pharma Inc.1997-09-172005-08-05Canada
Motilium Tab 10mgtablet10 mgoralJanssen Inc1990-12-312002-01-07Canada
Mylan-domperidonetablet10 mgoralMylan Pharmaceuticals Ulc2006-03-20Not applicableCanada
Nu-domperidone 10 Mg Tabletstablet10 mgoralNu Pharm Inc1998-03-182012-09-04Canada
PMS-domperidonetablet10 mgoralPharmascience Inc1997-11-13Not applicableCanada
Priva-domperidonetablet10 mgoralPharmapar IncNot applicableNot applicableCanada
Ran-domperidonetablet10 mgoralRanbaxy Pharmaceuticals Canada Inc.2005-07-05Not applicableCanada
Ratio-domperidonetablet10 mgoralTeva Canada Limited1993-12-31Not applicableCanada
Teva-domperidonetablet10 mgoralTeva Canada Limited1997-09-17Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-domperidone - Tab 10mgtablet10 mgoralApotex Inc1997-09-17Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EucitonRoux-Ocefa
MoperidonaSidus
MotiliumJanssen
NauzelinKyowa Hakko Kirin
Brand mixturesNot Available
SaltsNot Available
Categories
UNII5587267Z69
CAS number57808-66-9
WeightAverage: 425.911
Monoisotopic: 425.161852744
Chemical FormulaC22H24ClN5O2
InChI KeyInChIKey=FGXWKSZFVQUSTL-UHFFFAOYSA-N
InChI
InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)
IUPAC Name
5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-1,3-benzodiazol-1-yl)propyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one
SMILES
ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=CC=CC=C34)CC1)C(=O)N2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzimidazoles
Sub ClassNot Available
Direct ParentBenzimidazoles
Alternative Parents
Substituents
  • Benzimidazole
  • Chlorobenzene
  • 4-aminopiperidine
  • Benzenoid
  • Piperidine
  • N-substituted imidazole
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Urea
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor management of dyspepsia, heartburn, epigastric pain, nausea, and vomiting.
PharmacodynamicsDomperidone is a specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
Mechanism of actionDomperidone acts as a gastrointestinal emptying (delayed) adjunct and peristaltic stimulant. The gastroprokinetic properties of domperidone are related to its peripheral dopamine receptor blocking properties. Domperidone facilitates gastric emptying and decreases small bowel transit time by increasing esophageal and gastric peristalsis and by lowering esophageal sphincter pressure. Antiemetic: The antiemetic properties of domperidone are related to its dopamine receptor blocking activity at both the chemoreceptor trigger zone and at the gastric level. It has strong affinities for the D2 and D3 dopamine receptors, which are found in the chemoreceptor trigger zone, located just outside the blood brain barrier, which - among others - regulates nausea and vomiting
Related Articles
AbsorptionFast
Volume of distributionNot Available
Protein binding91%-93%
Metabolism
SubstrateEnzymesProduct
Domperidone
5-Chloro-1,3-dihydro-1-(4-piperidinyl)-2H-benzimidazol-2-oneDetails
Route of eliminationNot Available
Half life7 hours
ClearanceNot Available
ToxicitySide effects include galactorrhea, gynecomastia, or menstrual irregularities.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9967
Blood Brain Barrier+0.8686
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.7029
P-glycoprotein inhibitor IInhibitor0.7244
P-glycoprotein inhibitor IIInhibitor0.628
Renal organic cation transporterInhibitor0.6546
CYP450 2C9 substrateNon-substrate0.7974
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.6392
CYP450 1A2 substrateInhibitor0.8737
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8933
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.5577
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8695
Ames testNon AMES toxic0.6608
CarcinogenicityNon-carcinogens0.922
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.9828 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.7527
hERG inhibition (predictor II)Inhibitor0.917
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
  • Professional Co.
Dosage forms
FormRouteStrength
Tabletoral10 mg
Prices
Unit descriptionCostUnit
Domperidone bp powder55.2USD g
Ratio-Domperidone Maleate 10 mg Tablet0.16USD tablet
Apo-Domperidone 10 mg Tablet0.16USD tablet
Mylan-Domperidone 10 mg Tablet0.16USD tablet
Novo-Domperidone 10 mg Tablet0.16USD tablet
Nu-Domperidone 10 mg Tablet0.16USD tablet
Pms-Domperidone 10 mg Tablet0.15USD tablet
Ran-Domperidone 10 mg Tablet0.15USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point242.5 °CVanderberk, J., Kennis, L.E.J., Van der Aa, M.J.M.C. and Van Heertum, A.H.M.T.; U.S. Patents 4,066,772; January 3,1978; 4.1 10,333; August 29,1978; 4,126,687; November 21, 1978; 4,126,688; November 21,1978; 4,160,836; July 10,1979 and 4,175,129; November 20,1979; all assigned to Janssen Pharmaceutica NV (Belgium).
water solubility0.986 mg/LNot Available
logP3.90EL TAYER,N ET AL. (1985)
pKa7.9EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.0925 mg/mLALOGPS
logP3.7ALOGPS
logP2.9ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)12.52ChemAxon
pKa (Strongest Basic)7.03ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area67.92 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity119.37 m3·mol-1ChemAxon
Polarizability45.61 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Vanderberk, J., Kennis, L.E.J., Van der Aa, M.J.M.C. and Van Heertum, A.H.M.T.; U.S. Patents 4,066,772; January 3,1978; 4.1 10,333; August 29,1978; 4,126,687; November 21, 1978; 4,126,688; November 21,1978; 4,160,836; July 10,1979 and 4,175,129; November 20,1979; all assigned to Janssen Pharmaceutica NV (Belgium).

General References
  1. Silvers D, Kipnes M, Broadstone V, Patterson D, Quigley EM, McCallum R, Leidy NK, Farup C, Liu Y, Joslyn A: Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group. Clin Ther. 1998 May-Jun;20(3):438-53. [PubMed:9663360 ]
External Links
ATC CodesA03FA03
AHFS Codes
  • 56:32.00
  • 56:92.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.8 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Domperidone.
AbirateroneThe serum concentration of Domperidone can be increased when it is combined with Abiraterone.
AcetaminophenThe serum concentration of Domperidone can be increased when it is combined with Acetaminophen.
AfatinibThe serum concentration of Domperidone can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Domperidone can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Domperidone can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Domperidone can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Domperidone can be increased when it is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Domperidone.
AmantadineThe serum concentration of Domperidone can be increased when it is combined with Amantadine.
Aminohippuric acidThe serum concentration of Domperidone can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Domperidone can be increased when it is combined with Amiodarone.
AmiodaroneDomperidone may increase the QTc-prolonging activities of Amiodarone.
AmitriptylineThe serum concentration of Domperidone can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Domperidone can be increased when it is combined with Amlodipine.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Domperidone.
AmprenavirThe serum concentration of Domperidone can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Domperidone can be increased when it is combined with Amsacrine.
AnagrelideAnagrelide may increase the QTc-prolonging activities of Domperidone.
ApomorphineApomorphine may increase the QTc-prolonging activities of Domperidone.
AprepitantThe serum concentration of Domperidone can be increased when it is combined with Aprepitant.
ArformoterolArformoterol may increase the QTc-prolonging activities of Domperidone.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Domperidone.
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Domperidone.
ArtemetherDomperidone may increase the QTc-prolonging activities of Artemether.
AsenapineDomperidone may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe serum concentration of Domperidone can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Domperidone can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Domperidone can be increased when it is combined with Atenolol.
AtomoxetineThe serum concentration of Domperidone can be increased when it is combined with Atomoxetine.
AtorvastatinThe serum concentration of Domperidone can be increased when it is combined with Atorvastatin.
AzelastineThe serum concentration of Domperidone can be increased when it is combined with Azelastine.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Domperidone.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Domperidone.
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Domperidone.
BenzocaineThe serum concentration of Domperidone can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Domperidone can be increased when it is combined with Bepridil.
BetaxololThe metabolism of Domperidone can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Domperidone can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Domperidone can be increased when it is combined with Biperiden.
BoceprevirThe serum concentration of Domperidone can be increased when it is combined with Boceprevir.
BortezomibThe serum concentration of Domperidone can be increased when it is combined with Bortezomib.
BosentanThe serum concentration of Domperidone can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Domperidone can be increased when it is combined with Bosutinib.
BromocriptineThe serum concentration of Domperidone can be increased when it is combined with Bromocriptine.
BuprenorphineThe serum concentration of Domperidone can be increased when it is combined with Buprenorphine.
BupropionThe metabolism of Domperidone can be decreased when combined with Bupropion.
BuserelinBuserelin may increase the QTc-prolonging activities of Domperidone.
BuspironeThe serum concentration of Domperidone can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Domperidone can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Domperidone can be increased when it is combined with Caffeine.
CanagliflozinThe serum concentration of Domperidone can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Domperidone can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Domperidone can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Domperidone can be decreased when it is combined with Carbamazepine.
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Domperidone.
CarvedilolThe serum concentration of Domperidone can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Domperidone can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Domperidone can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Domperidone can be increased when it is combined with Ceritinib.
ChloroquineChloroquine may increase the QTc-prolonging activities of Domperidone.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Domperidone.
ChlorpropamideThe serum concentration of Domperidone can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Domperidone can be increased when it is combined with Chlorprothixene.
CholecalciferolThe metabolism of Domperidone can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Domperidone can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Domperidone can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Domperidone can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Domperidone can be decreased when it is combined with Cimetidine.
CinacalcetThe metabolism of Domperidone can be decreased when combined with Cinacalcet.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Domperidone.
CisaprideCisapride may increase the QTc-prolonging activities of Domperidone.
CitalopramCitalopram may increase the QTc-prolonging activities of Domperidone.
ClarithromycinThe serum concentration of Domperidone can be increased when it is combined with Clarithromycin.
ClemastineThe serum concentration of Domperidone can be increased when it is combined with Clemastine.
ClobazamThe metabolism of Domperidone can be decreased when combined with Clobazam.
ClofazimineThe serum concentration of Domperidone can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Domperidone can be increased when it is combined with Clomipramine.
ClopidogrelThe metabolism of Domperidone can be decreased when combined with Clopidogrel.
ClotrimazoleThe serum concentration of Domperidone can be increased when it is combined with Clotrimazole.
ClozapineClozapine may increase the QTc-prolonging activities of Domperidone.
CobicistatThe serum concentration of Domperidone can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Domperidone can be decreased when combined with Cocaine.
ColchicineThe serum concentration of Domperidone can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Domperidone can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Domperidone can be increased when it is combined with Conivaptan.
CrizotinibThe serum concentration of Domperidone can be increased when it is combined with Crizotinib.
CyclophosphamideThe serum concentration of Domperidone can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Domperidone can be increased when it is combined with Cyclosporine.
Cyproterone acetateThe serum concentration of Domperidone can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Domperidone can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Domperidone can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Domperidone can be increased when it is combined with Dactinomycin.
DarifenacinThe metabolism of Domperidone can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Domperidone can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Domperidone can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Domperidone can be decreased when it is combined with Daunorubicin.
DeferasiroxThe serum concentration of Domperidone can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Domperidone.
DelavirdineThe serum concentration of Domperidone can be increased when it is combined with Delavirdine.
DesfluraneDesflurane may increase the QTc-prolonging activities of Domperidone.
DesipramineThe serum concentration of Domperidone can be increased when it is combined with Desipramine.
DesloratadineThe serum concentration of Domperidone can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Domperidone can be decreased when it is combined with Dexamethasone.
DextromethorphanThe serum concentration of Domperidone can be increased when it is combined with Dextromethorphan.
DiclofenacThe serum concentration of Domperidone can be increased when it is combined with Diclofenac.
DigoxinThe serum concentration of Domperidone can be decreased when it is combined with Digoxin.
DihydroergotamineThe serum concentration of Domperidone can be increased when it is combined with Dihydroergotamine.
DiltiazemThe serum concentration of Domperidone can be increased when it is combined with Diltiazem.
DiphenhydramineThe metabolism of Domperidone can be decreased when combined with Diphenhydramine.
DipyridamoleThe serum concentration of Domperidone can be increased when it is combined with Dipyridamole.
DisopyramideDisopyramide may increase the QTc-prolonging activities of Domperidone.
DofetilideDofetilide may increase the QTc-prolonging activities of Domperidone.
DolasetronDolasetron may increase the QTc-prolonging activities of Domperidone.
DoxazosinThe serum concentration of Domperidone can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Domperidone can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Domperidone can be decreased when it is combined with Doxorubicin.
DoxycyclineThe serum concentration of Domperidone can be increased when it is combined with Doxycycline.
DronabinolThe serum concentration of Domperidone can be increased when it is combined with Dronabinol.
DronedaroneThe serum concentration of Domperidone can be increased when it is combined with Dronedarone.
DronedaroneDomperidone may increase the QTc-prolonging activities of Dronedarone.
DroperidolDroperidol may increase the QTc-prolonging activities of Domperidone.
DuloxetineThe metabolism of Domperidone can be decreased when combined with Duloxetine.
EfavirenzThe serum concentration of Domperidone can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Domperidone can be increased when it is combined with Elbasvir.
EliglustatDomperidone may increase the QTc-prolonging activities of Eliglustat.
EnalaprilThe serum concentration of Domperidone can be increased when it is combined with Enalapril.
EnzalutamideThe serum concentration of Domperidone can be increased when it is combined with Enzalutamide.
ErgonovineThe serum concentration of Domperidone can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Domperidone can be increased when it is combined with Ergotamine.
EribulinEribulin may increase the QTc-prolonging activities of Domperidone.
ErythromycinThe serum concentration of Domperidone can be increased when it is combined with Erythromycin.
EscitalopramEscitalopram may increase the QTc-prolonging activities of Domperidone.
Eslicarbazepine acetateThe serum concentration of Domperidone can be decreased when it is combined with Eslicarbazepine acetate.
EstramustineThe serum concentration of Domperidone can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Domperidone can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Domperidone can be decreased when it is combined with Estrone.
EtoposideThe serum concentration of Domperidone can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Domperidone can be decreased when it is combined with Etravirine.
EzogabineEzogabine may increase the QTc-prolonging activities of Domperidone.
FamotidineFamotidine may increase the QTc-prolonging activities of Domperidone.
FelbamateFelbamate may increase the QTc-prolonging activities of Domperidone.
FelodipineThe serum concentration of Domperidone can be increased when it is combined with Felodipine.
FentanylThe serum concentration of Domperidone can be increased when it is combined with Fentanyl.
FexofenadineThe serum concentration of Domperidone can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Domperidone can be increased when it is combined with Fidaxomicin.
FingolimodFingolimod may increase the QTc-prolonging activities of Domperidone.
FlecainideFlecainide may increase the QTc-prolonging activities of Domperidone.
FluconazoleThe serum concentration of Domperidone can be increased when it is combined with Fluconazole.
FluoxetineFluoxetine may increase the QTc-prolonging activities of Domperidone.
FlupentixolFlupentixol may increase the QTc-prolonging activities of Domperidone.
FluphenazineThe serum concentration of Domperidone can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Domperidone can be increased when it is combined with Flurazepam.
FluvoxamineThe serum concentration of Domperidone can be increased when it is combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Domperidone.
FosamprenavirThe serum concentration of Domperidone can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Domperidone can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Domperidone.
FosphenytoinThe metabolism of Domperidone can be increased when combined with Fosphenytoin.
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Domperidone.
Fusidic AcidThe serum concentration of Domperidone can be increased when it is combined with Fusidic Acid.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Domperidone.
GalantamineGalantamine may increase the QTc-prolonging activities of Domperidone.
GefitinibThe serum concentration of Domperidone can be increased when it is combined with Gefitinib.
GemfibrozilThe metabolism of Domperidone can be decreased when combined with Gemfibrozil.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Domperidone.
GenisteinThe serum concentration of Domperidone can be increased when it is combined with Genistein.
GlyburideThe serum concentration of Domperidone can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Domperidone can be increased when it is combined with Glycerol.
GoserelinGoserelin may increase the QTc-prolonging activities of Domperidone.
Gramicidin DThe serum concentration of Domperidone can be increased when it is combined with Gramicidin D.
GranisetronGranisetron may increase the QTc-prolonging activities of Domperidone.
GrepafloxacinThe serum concentration of Domperidone can be increased when it is combined with Grepafloxacin.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Domperidone.
HistrelinHistrelin may increase the QTc-prolonging activities of Domperidone.
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Domperidone.
HydrocortisoneThe serum concentration of Domperidone can be increased when it is combined with Hydrocortisone.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Domperidone.
IbandronateIbandronate may increase the QTc-prolonging activities of Domperidone.
IbutilideIbutilide may increase the QTc-prolonging activities of Domperidone.
IdelalisibThe serum concentration of Domperidone can be increased when it is combined with Idelalisib.
IloperidoneDomperidone may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe serum concentration of Domperidone can be increased when it is combined with Imatinib.
ImipramineThe serum concentration of Domperidone can be increased when it is combined with Imipramine.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Domperidone.
IndapamideIndapamide may increase the QTc-prolonging activities of Domperidone.
IndinavirThe serum concentration of Domperidone can be increased when it is combined with Indinavir.
IndomethacinThe serum concentration of Domperidone can be increased when it is combined with Indomethacin.
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Domperidone.
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Domperidone.
IrbesartanThe metabolism of Domperidone can be decreased when combined with Irbesartan.
IsavuconazoniumThe serum concentration of Domperidone can be increased when it is combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Domperidone.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Domperidone.
IsoniazidThe metabolism of Domperidone can be decreased when combined with Isoniazid.
IsradipineThe serum concentration of Domperidone can be increased when it is combined with Isradipine.
ItraconazoleThe serum concentration of Domperidone can be increased when it is combined with Itraconazole.
IvabradineIvabradine may increase the QTc-prolonging activities of Domperidone.
IvacaftorThe serum concentration of Domperidone can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Domperidone can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Domperidone can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Domperidone can be increased when it is combined with Ketoconazole.
LansoprazoleThe serum concentration of Domperidone can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Domperidone can be increased when it is combined with Lapatinib.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Domperidone.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Domperidone.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Domperidone.
LevothyroxineThe serum concentration of Domperidone can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Domperidone can be increased when it is combined with Lidocaine.
LiothyronineThe serum concentration of Domperidone can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Domperidone can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Domperidone can be increased when it is combined with Lisinopril.
LithiumLithium may increase the QTc-prolonging activities of Domperidone.
LomitapideThe serum concentration of Domperidone can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Domperidone can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Domperidone can be increased when it is combined with Lopinavir.
LopinavirDomperidone may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe serum concentration of Domperidone can be increased when it is combined with Loratadine.
LorcaserinThe metabolism of Domperidone can be decreased when combined with Lorcaserin.
LosartanThe serum concentration of Domperidone can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Domperidone can be increased when it is combined with Lovastatin.
LuliconazoleThe serum concentration of Domperidone can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Domperidone can be decreased when it is combined with Lumacaftor.
LumefantrineDomperidone may increase the QTc-prolonging activities of Lumefantrine.
MaprotilineThe serum concentration of Domperidone can be increased when it is combined with Maprotiline.
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Domperidone.
MebendazoleThe serum concentration of Domperidone can be increased when it is combined with Mebendazole.
MefloquineThe serum concentration of Domperidone can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Domperidone can be increased when it is combined with Megestrol acetate.
MeprobamateThe serum concentration of Domperidone can be increased when it is combined with Meprobamate.
MethadoneMethadone may increase the QTc-prolonging activities of Domperidone.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Domperidone.
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Domperidone.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Domperidone.
MetoprololThe serum concentration of Domperidone can be increased when it is combined with Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Domperidone.
MexiletineThe metabolism of Domperidone can be decreased when combined with Mexiletine.
MibefradilThe serum concentration of Domperidone can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Domperidone can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Domperidone can be decreased when it is combined with Midazolam.
MifepristoneThe serum concentration of Domperidone can be increased when it is combined with Mifepristone.
MifepristoneDomperidone may increase the QTc-prolonging activities of Mifepristone.
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Domperidone.
MirabegronThe metabolism of Domperidone can be decreased when combined with Mirabegron.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Domperidone.
MitomycinThe serum concentration of Domperidone can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Domperidone can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Domperidone can be decreased when it is combined with Mitoxantrone.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Domperidone.
ModafinilThe serum concentration of Domperidone can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the QTc-prolonging activities of Domperidone.
MorphineThe serum concentration of Domperidone can be increased when it is combined with Morphine.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Domperidone.
NafcillinThe serum concentration of Domperidone can be decreased when it is combined with Nafcillin.
NaltrexoneThe serum concentration of Domperidone can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Domperidone can be increased when it is combined with Naringenin.
NefazodoneThe serum concentration of Domperidone can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Domperidone can be increased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Domperidone can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Domperidone can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Domperidone can be increased when it is combined with Nevirapine.
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Domperidone.
NicardipineThe serum concentration of Domperidone can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Domperidone can be decreased when it is combined with Nifedipine.
NilotinibThe serum concentration of Domperidone can be increased when it is combined with Nilotinib.
NilotinibDomperidone may increase the QTc-prolonging activities of Nilotinib.
NisoldipineThe serum concentration of Domperidone can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Domperidone can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Domperidone can be increased when it is combined with Nitrendipine.
NorethisteroneThe serum concentration of Domperidone can be decreased when it is combined with Norethisterone.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Domperidone.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Domperidone.
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Domperidone.
OctreotideOctreotide may increase the QTc-prolonging activities of Domperidone.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Domperidone.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Domperidone.
OlaparibThe serum concentration of Domperidone can be increased when it is combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Domperidone.
OmeprazoleThe serum concentration of Domperidone can be increased when it is combined with Omeprazole.
OndansetronOndansetron may increase the QTc-prolonging activities of Domperidone.
OsimertinibThe serum concentration of Domperidone can be increased when it is combined with Osimertinib.
OxytocinOxytocin may increase the QTc-prolonging activities of Domperidone.
P-NitrophenolThe serum concentration of Domperidone can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Domperidone can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Domperidone can be increased when it is combined with Palbociclib.
PaliperidoneDomperidone may increase the QTc-prolonging activities of Paliperidone.
Palmitic AcidThe serum concentration of Domperidone can be increased when it is combined with Palmitic Acid.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Domperidone.
PantoprazoleThe serum concentration of Domperidone can be increased when it is combined with Pantoprazole.
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Domperidone.
ParoxetineThe serum concentration of Domperidone can be increased when it is combined with Paroxetine.
PasireotidePasireotide may increase the QTc-prolonging activities of Domperidone.
PazopanibPazopanib may increase the QTc-prolonging activities of Domperidone.
Peginterferon alfa-2bThe serum concentration of Domperidone can be decreased when it is combined with Peginterferon alfa-2b.
PentamidinePentamidine may increase the QTc-prolonging activities of Domperidone.
PentobarbitalThe metabolism of Domperidone can be increased when combined with Pentobarbital.
PerflutrenPerflutren may increase the QTc-prolonging activities of Domperidone.
PerindoprilThe serum concentration of Domperidone can be increased when it is combined with Perindopril.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Domperidone.
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Domperidone.
PhenobarbitalThe serum concentration of Domperidone can be decreased when it is combined with Phenobarbital.
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Domperidone.
PhenytoinThe metabolism of Domperidone can be increased when combined with Phenytoin.
PimozidePimozide may increase the QTc-prolonging activities of Domperidone.
PioglitazoneThe metabolism of Domperidone can be decreased when combined with Pioglitazone.
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Domperidone.
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Domperidone.
Platelet Activating FactorThe serum concentration of Domperidone can be decreased when it is combined with Platelet Activating Factor.
PonatinibThe serum concentration of Domperidone can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Domperidone can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Domperidone can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Domperidone can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Domperidone can be increased when it is combined with Prednisone.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Domperidone.
PrimidoneThe metabolism of Domperidone can be increased when combined with Primidone.
ProbenecidThe serum concentration of Domperidone can be increased when it is combined with Probenecid.
ProcainamideProcainamide may increase the QTc-prolonging activities of Domperidone.
ProgesteroneThe serum concentration of Domperidone can be decreased when it is combined with Progesterone.
PromazinePromazine may increase the QTc-prolonging activities of Domperidone.
PromethazineThe serum concentration of Domperidone can be increased when it is combined with Promethazine.
PropafenonePropafenone may increase the QTc-prolonging activities of Domperidone.
PropofolPropofol may increase the QTc-prolonging activities of Domperidone.
PropranololThe serum concentration of Domperidone can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Domperidone can be increased when it is combined with Protriptyline.
QuazepamThe serum concentration of Domperidone can be increased when it is combined with Quazepam.
QuercetinThe serum concentration of Domperidone can be increased when it is combined with Quercetin.
QuetiapineDomperidone may increase the QTc-prolonging activities of Quetiapine.
QuinacrineThe serum concentration of Domperidone can be increased when it is combined with Quinacrine.
QuinidineQuinidine may increase the QTc-prolonging activities of Domperidone.
QuinineQuinine may increase the QTc-prolonging activities of Domperidone.
RabeprazoleThe metabolism of Domperidone can be decreased when combined with Rabeprazole.
RanitidineThe serum concentration of Domperidone can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Domperidone can be increased when it is combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Domperidone.
ReboxetineThe serum concentration of Domperidone can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Domperidone can be increased when it is combined with Regorafenib.
ReserpineThe serum concentration of Domperidone can be decreased when it is combined with Reserpine.
RifabutinThe metabolism of Domperidone can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Domperidone can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Domperidone can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Domperidone can be increased when it is combined with Rilpivirine.
RisperidoneRisperidone may increase the QTc-prolonging activities of Domperidone.
RitonavirThe serum concentration of Domperidone can be increased when it is combined with Ritonavir.
RolapitantThe serum concentration of Domperidone can be increased when it is combined with Rolapitant.
RopiniroleThe metabolism of Domperidone can be decreased when combined with Ropinirole.
RosiglitazoneThe metabolism of Domperidone can be decreased when combined with Rosiglitazone.
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Domperidone.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Domperidone.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Domperidone.
SaquinavirThe serum concentration of Domperidone can be increased when it is combined with Saquinavir.
ScopolamineThe serum concentration of Domperidone can be increased when it is combined with Scopolamine.
SecobarbitalThe metabolism of Domperidone can be increased when combined with Secobarbital.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Domperidone.
SertralineThe serum concentration of Domperidone can be increased when it is combined with Sertraline.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Domperidone.
SildenafilThe serum concentration of Domperidone can be increased when it is combined with Sildenafil.
SiltuximabThe serum concentration of Domperidone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Domperidone can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Domperidone can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Domperidone can be decreased when it is combined with Sirolimus.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Domperidone.
SorafenibThe serum concentration of Domperidone can be increased when it is combined with Sorafenib.
SotalolSotalol may increase the QTc-prolonging activities of Domperidone.
SpironolactoneThe serum concentration of Domperidone can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Domperidone can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Domperidone can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Domperidone can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Domperidone can be decreased when it is combined with Streptozocin.
SulfamethoxazoleThe metabolism of Domperidone can be decreased when combined with Sulfamethoxazole.
SulfinpyrazoneThe serum concentration of Domperidone can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe serum concentration of Domperidone can be increased when it is combined with Sulfisoxazole.
SumatriptanThe serum concentration of Domperidone can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Domperidone can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Domperidone can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Domperidone can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Domperidone can be decreased when it is combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Domperidone can be increased when it is combined with Taurocholic Acid.
TelaprevirThe serum concentration of Domperidone can be increased when it is combined with Telaprevir.
TelavancinTelavancin may increase the QTc-prolonging activities of Domperidone.
TelithromycinThe serum concentration of Domperidone can be increased when it is combined with Telithromycin.
TelmisartanThe serum concentration of Domperidone can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of Domperidone can be increased when it is combined with Temsirolimus.
TenofovirThe metabolism of Domperidone can be decreased when combined with Tenofovir.
TerazosinThe serum concentration of Domperidone can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Domperidone can be decreased when combined with Terbinafine.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Domperidone.
TerfenadineThe serum concentration of Domperidone can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Domperidone can be decreased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Domperidone can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Domperidone can be increased when it is combined with Testosterone.
TetrabenazineDomperidone may increase the QTc-prolonging activities of Tetrabenazine.
TheophyllineThe metabolism of Domperidone can be decreased when combined with Theophylline.
ThioridazineThioridazine may increase the QTc-prolonging activities of Domperidone.
ThiotepaThe metabolism of Domperidone can be decreased when combined with Thiotepa.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Domperidone.
TicagrelorThe serum concentration of Domperidone can be increased when it is combined with Ticagrelor.
TiclopidineThe serum concentration of Domperidone can be increased when it is combined with Ticlopidine.
TipranavirThe metabolism of Domperidone can be decreased when combined with Tipranavir.
TizanidineTizanidine may increase the QTc-prolonging activities of Domperidone.
TocilizumabThe serum concentration of Domperidone can be decreased when it is combined with Tocilizumab.
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Domperidone.
TolterodineTolterodine may increase the QTc-prolonging activities of Domperidone.
TolvaptanThe serum concentration of Domperidone can be increased when it is combined with Tolvaptan.
ToremifeneToremifene may increase the QTc-prolonging activities of Domperidone.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Domperidone.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Domperidone.
TrazodoneThe serum concentration of Domperidone can be decreased when it is combined with Trazodone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Domperidone.
TrifluoperazineThe serum concentration of Domperidone can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Domperidone can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Domperidone can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Domperidone can be increased when it is combined with Trimipramine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Domperidone.
TroleandomycinThe serum concentration of Domperidone can be increased when it is combined with Troleandomycin.
VandetanibDomperidone may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Domperidone.
VemurafenibDomperidone may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe serum concentration of Domperidone can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Domperidone can be increased when it is combined with Verapamil.
VilanterolVilanterol may increase the QTc-prolonging activities of Domperidone.
VinblastineThe serum concentration of Domperidone can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Domperidone can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Domperidone can be increased when it is combined with Vinorelbine.
VoriconazoleThe serum concentration of Domperidone can be increased when it is combined with Voriconazole.
VorinostatVorinostat may increase the QTc-prolonging activities of Domperidone.
ZimelidineThe serum concentration of Domperidone can be increased when it is combined with Zimelidine.
ZiprasidoneThe serum concentration of Domperidone can be increased when it is combined with Ziprasidone.
ZiprasidoneDomperidone may increase the QTc-prolonging activities of Ziprasidone.
ZuclopenthixolDomperidone may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Take 15 to 30 minutes before meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Cavallotti C, Nuti F, Bruzzone P, Mancone M: Age-related changes in dopamine D2 receptors in rat heart and coronary vessels. Clin Exp Pharmacol Physiol. 2002 May-Jun;29(5-6):412-8. [PubMed:12010185 ]
  2. Osinski MA, Uchic ME, Seifert T, Shaughnessy TK, Miller LN, Nakane M, Cox BF, Brioni JD, Moreland RB: Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets. Pharmacol Biochem Behav. 2005 May;81(1):211-9. [PubMed:15894081 ]
  3. de Mey C, Enterling D, Meineke I, Yeulet S: Interactions between domperidone and ropinirole, a novel dopamine D2-receptor agonist. Br J Clin Pharmacol. 1991 Oct;32(4):483-8. [PubMed:1683559 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Ali I, Gupta VK, Singh P, Pant HV: Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31. doi: 10.1016/j.talanta.2005.06.027. Epub 2005 Jul 22. [PubMed:18970411 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G: Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther. 1994 Jan;268(1):417-26. [PubMed:8301582 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Chang SY, Fancher RM, Zhang H, Gan J: Mechanism-based inhibition of human cytochrome P4503A4 by domperidone. Xenobiotica. 2010 Feb;40(2):138-45. doi: 10.3109/00498250903406762. [PubMed:20082577 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Simard C, Michaud V, Gibbs B, Masse R, Lessard E, Turgeon J: Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica. 2004 Nov-Dec;34(11-12):1013-23. [PubMed:15801545 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186 ]
  2. Schinkel AH, Wagenaar E, Mol CA, van Deemter L: P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 1996 Jun 1;97(11):2517-24. [PubMed:8647944 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23